Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Unaudited)

v3.10.0.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Retained Deficit
Beginning balance (in shares) at Dec. 31, 2016   158,829,816      
Beginning balance at Dec. 31, 2016 $ 2,183,892 $ 1,588 $ 3,946,442 $ (53,058) $ (1,711,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 260,391       260,391
Other Comprehensive Income (Loss) 5,887     5,887  
Stock-based Compensation 5,233   5,233    
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses (in shares)   23,852,117      
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses 459,436 $ 239 459,197    
Issuance of Restricted Stock (in shares)   172,988      
Issuance of Restricted Stock 0 $ 1 (1)    
Ending balance (in shares) at Jun. 30, 2017   182,854,921      
Ending balance at Jun. 30, 2017 $ 2,914,839 $ 1,828 4,410,871 (47,171) (1,450,689)
Beginning balance (in shares) at Dec. 31, 2017 183,105,910 183,105,910      
Beginning balance at Dec. 31, 2017 $ 3,101,614 $ 1,831 4,416,250 (40,539) (1,275,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 201,409       201,409
Other Comprehensive Income (Loss) (8,867)     (8,867)  
Stock-based Compensation 6,040   6,040    
Shares Repurchased (in shares)   (10,104,872)      
Shares Repurchased (104,997) $ (101) (104,896)    
Issuance of Restricted Stock (in shares)   301,017      
Issuance of Restricted Stock $ 0 $ 3 (3)    
Ending balance (in shares) at Jun. 30, 2018 173,302,055 173,302,055      
Ending balance at Jun. 30, 2018 $ 3,195,199 $ 1,733 $ 4,317,391 $ (49,406) $ (1,074,519)